Billiontoone, Inc. (NASDAQ:BLLN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Billiontoone, Inc. (NASDAQ:BLLN) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $137.8333.

A number of research firms have commented on BLLN. Wall Street Zen raised shares of Billiontoone to a “hold” rating in a research note on Saturday, November 15th. Wells Fargo & Company assumed coverage on shares of Billiontoone in a report on Monday, December 1st. They set an “equal weight” rating and a $110.00 price objective for the company. Jefferies Financial Group assumed coverage on Billiontoone in a research note on Monday, December 1st. They issued a “hold” rating and a $117.00 target price on the stock. BTIG Research restated a “buy” rating and set a $160.00 price target on shares of Billiontoone in a research report on Wednesday, December 10th. Finally, Zacks Research upgraded Billiontoone to a “hold” rating in a report on Tuesday, December 2nd.

Billiontoone Price Performance

Shares of NASDAQ BLLN opened at $86.34 on Friday. Billiontoone has a twelve month low of $81.51 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06). The firm had revenue of $83.52 million during the quarter, compared to analysts’ expectations of $82.86 million.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.